The skeletal muscle environment and its role in immunity and tolerance to AAV vector-mediated gene transfer

Current Gene Therapy

Volumn 15, Issue 4, 2015, Pages 381-394

  Boisgérault, Florence ^a   Mingozzi, Federico ^a,b  

^a GÉNÉTHON   (France)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

AAV vectors; Clinical trials; Immune responses; Muscle; Tolerance

Indexed keywords

NEUTRALIZING ANTIBODY; PARVOVIRUS VECTOR;

ARTICLE; CLINICAL TRIAL (TOPIC); ENZYME DEFICIENCY; GENE THERAPY; GENE TRANSFER; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; IMMUNOMODULATION; METABOLIC DISORDER; MYOSITIS; NEUROMUSCULAR DISEASE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; SEROTYPE; SKELETAL MUSCLE; T LYMPHOCYTE; TRANSGENE; ADMINISTRATION AND DOSAGE; ANIMAL; DEPENDOPARVOVIRUS; GENE VECTOR; GENETICS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; MOUSE; NEUROMUSCULAR DISEASES; PROCEDURES; VIROLOGY;

ADENO-ASSOCIATED VIRUS;

ANIMALS; DEPENDOVIRUS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HUMANS; IMMUNE TOLERANCE; INJECTIONS, INTRAMUSCULAR; MICE; MUSCLE, SKELETAL; NEUROMUSCULAR DISEASES; TRANSGENES;

EID: 84938683119     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/1566523215666150630121750     Document Type: Article

References (167)

1. Muzyczka N, Berns KI. Parvoviridae: The viruses and their replication. 4th ed. Knipe DM, Howley PM, editors. Philadelphia: Lippincott, Williams and Wilkins; 2001.
2. Mingozzi F, High KA. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Na rev Genetics 2011; 12(5): 341-55.
3. Buning H. Gene therapy enters the pharma market: the short story of a long journey. EMBO molecular medicine. 2013; 5(1): 1-3.
4. Kessler PD, Podsakoff GM, Chen X, et al. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci U S A 1996; 93(24): 14082-7.
5. Xiao X, Li J, Samulski RJ. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol 1996; 70(11): 8098-108.
6. Fraites TJ, Jr., Schleissing MR, Shanely RA, et al. Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors. Mol Ther 2002; 5(5 Pt 1): 571-8.
7. Ross CJ, Twisk J, Bakker AC, et al. Correction of feline lipoprotein lipase deficiency with adeno-associated virus serotype 1-mediated gene transfer of the lipoprotein lipase S447X beneficial mutation. Hum Gene Ther 2006; 17(5): 487-99.
8. Song S, Morgan M, Ellis T, et al. Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adenoassociated virus vectors. Proc Natl Acad Sci U S A 1998; 95(24): 14384-8.
9. Herzog RW, Hagstrom JN, Kung SH, et al. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Natl Acad Sci U S A 1997; 94(11): 5804-9.
10. Bowles DE, McPhee SW, Li C, et al. Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol Ther 2012; 20(2): 443-55.
11. Foster H, Sharp PS, Athanasopoulos T, et al. Codon and mRNA sequence optimization of microdystrophin transgenes improves expression and physiological outcome in dystrophic mdx mice following AAV2/8 gene transfer. Mol Ther 2008; 16(11): 1825-32.
12. Lai Y, Yue Y, Liu M, Ghosh A, et al. Efficient in vivo gene expression by trans-splicing adeno-associated viral vectors. Nature biotechno 2005; 23(11): 1435-9.
13. Le Guiner C, Montus M, Servais L, et al. Forelimb treatment in a large cohort of dystrophic dogs supports delivery of a recombinant AAV for exon skipping in Duchenne patients. Mol Ther 2014; 22(11): 1923-35.
14. Lostal W, Bartoli M, Bourg N, et al. Efficient recovery of dysferlin deficiency by dual adeno-associated vector-mediated gene transfer. Human mol genetics 2010; 19(10): 1897-907.
15. Louboutin JP, Wang L, Wilson JM. Gene transfer into skeletal muscle using novel AAV serotypes. j gene med 2005; 7(4): 442-51.
16. Wang B, Li J, Xiao X. Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc Natl Acad Sci U S A 2000; 97(25): 13714-9.
17. Gregorevic P, Allen JM, Minami E, Blankinship MJ, et al. rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat Med 2006; 12(7): 787-9.
18. Matzinger P. The danger model: a renewed sense of self. Sci 2002; 296(5566): 301-5.
19. Calcedo R, Morizono H, Wang L, et al. Adeno-associated virus antibody profiles in newborns, children, and adolescents. Clin Vaccine Immunol 2011; 18(9): 1586-8.
20. Erles K, Sebokova P, Schlehofer JR. Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J Med Virol 1999; 59(3): 406-11.
21. Li C, Narkbunnam N, Samulski RJ, Asokan A, et al. Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia. Gene therapy 2011.
22. Boutin S, Monteilhet V, Veron P, Leborgne C, et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther 2010; 21(6): 704-12.
23. Calcedo R, Vandenberghe LH, Gao G, Lin J, Wilson JM. Worldwide epidemiology of neutralizing antibodies to adenoassociated viruses. J Infect Dis 2009; 199(3): 381-90.
24. Veron P, Leborgne C, Monteilhet V, Boutin S, et al. Humoral and cellular capsid-specific immune responses to adeno-associated virus type 1 in randomized healthy donors. J immunol 2012; 188(12): 6418-24.
25. Hoggan MD, Blacklow NR, Rowe WP. Studies of small DNA viruses found in various adenovirus preparations: physical, biological, and immunological characteristics. Proc Natl Acad Sci U S A 1966; 55(6): 1467-74.
26. Rogers GL, Martino AT, Aslanidi GV, et al. Innate Immune Responses to AAV Vectors. Front Microbiol 2011; 2: 194.
27. Basner-Tschakarjan E, Mingozzi F. Cell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential Solutions. Frontiers in immunol 2014; 5: 350.
28. Masat E, Pavani G, Mingozzi F. Humoral immunity to AAV vectors in gene therapy: challenges and potential solutions. Discov med 2013; 15(85): 379-89.
29. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006; 12(3): 342-7.
30. Mingozzi F, Maus MV, Hui DJ, et al. CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med 2007; 13(4): 419-22.
31. Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirusassociated virus vector-mediated gene transfer in hemophilia B. New Eng j med 2011; 365(25): 2357-65.
32. Nathwani AC, Reiss UM, Tuddenham EG, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. New Eng j med 2014; 371(21): 1994-2004.
33. Gao GP, Alvira MR, Wang L, et al. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A 2002; 99(18): 11854-9.
34. Mingozzi F, Chen Y, Edmonson SC, et al. Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissue. Gene ther 2013; 20(4): 417-24.
35. Arruda VR, Stedman HH, Haurigot V, et al. Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B. Blood 2010; 115(23): 4678-88.
36. Jiang H, Couto LB, Patarroyo-White S, et al. Effects of transient immunosuppression on adenoassociated, virus-mediated, liverdirected gene transfer in rhesus macaques and implications for human gene therapy. Blood 2006; 108(10): 3321-8.
37. Scallan CD, Jiang H, Liu T, Patarroyo-White S, et al. Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice. Blood 2006; 107(5): 1810- 7.
38. Foust KD, Nurre E, Montgomery CL, et al. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat biotechno 2009; 27(1): 59-65.
39. Bainbridge JW, Smith AJ, Barker SS, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis.New Eng j med 2008; 358(21): 2231-9.
40. Cideciyan AV, Aleman TS, Boye SL, et al. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci U S A 2008; 105(39): 15112-7.
41. Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. New Eng j med 2008; 358(21): 2240-8.
42. Shin JH, Pan X, Hakim CH, et al. Microdystrophin ameliorates muscular dystrophy in the canine model of duchenne muscular dystrophy. Mol Ther 2013; 21(4): 750-7.
43. Childers MK, Joubert R, Poulard K, Moal C, et al. Gene therapy prolongs survival and restores function in murine and canine models of myotubular myopathy. Sci Transl Med 2014; 6(220): 220ra10.
44. Jaski BE, Jessup ML, Mancini DM, et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. J Card Fail 2009; 15(3): 171-81.
45. Arnett AL, Konieczny P, Ramos JN, Hall J, et al. Adenoassociated viral (AAV) vectors do not efficiently target muscle satellite cells. Mol Ther Methods Clin Dev 2014; 1.
46. Dupont JB, Tournaire B, Georger C, Marolleau B, et al. Short-lived recombinant adeno-associated virus transgene expression in dystrophic muscle is associated with oxidative damage to transgene mRNA. Mol Ther Methods Clin Dev 2015; 2: 15010.
47. McIntosh JH, Cochrane M, Cobbold S, Waldmann H, et al. Successful attenuation of humoral immunity to viral capsid and transgenic protein following AAV-mediated gene transfer with a non-depleting CD4 antibody and cyclosporine. Gene ther 2012; 19(1): 78-85.
48. Han SO, Li S, Brooks ED, Masat E, Leborgne C, et al. Enhanced Efficacy from Gene Therapy in Pompe Disease Using Co-receptor Blockade. Hum Gene Ther 2014.
49. Unzu C, Hervas-Stubbs S, Sampedro A, et al. Transient and intensive pharmacological immunosuppression fails to improve AAV-based liver gene transfer in non-human primates. J translational med 2012; 10: 122.
50. Mingozzi F, Hasbrouck NC, Basner-Tschakarjan E, et al. Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. Blood 2007; 110(7): 2334-41.
51. Montenegro-Miranda PS, ten Bloemendaal L, et al. Mycophenolate mofetil impairs transduction of single-stranded adeno-associated viral vectors. Hum Gene Ther 2011; 22(5): 605- 12.
52. Monteilhet V, Saheb S, Boutin S, Leborgne C, et al. A 10 Patient Case Report on the Impact of Plasmapheresis Upon Neutralizing Factors Against Adeno-associated Virus (AAV) Types 1, 2, 6, and 8. Mol Ther 2011.
53. Chicoine LG, Montgomery CL, Bremer WG, et al. Plasmapheresis eliminates the negative impact of AAV antibodies on microdystrophin gene expression following vascular delivery. Mol Ther 2014; 22(2): 338-47.
54. Hurlbut GD, Ziegler RJ, Nietupski JB, et al. Preexisting immunity and low expression in primates highlight translational challenges for liver-directed AAV8-mediated gene therapy. Mol Ther 2010; 18(11): 1983-94.
55. Mingozzi F, Anguela XM, Pavani G, et al. Overcoming preexisting humoral immunity to AAV using capsid decoys. Sci Transl Med 2013; 5(194): 194ra92.
56. Pien GC, Basner-Tschakarjan E, Hui DJ, et al. Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors. J Clin Invest 2009; 119(6): 1688-95.
57. Finn JD, Hui D, Downey HD, Dunn D, et al. Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transduction. Mol Ther 2010; 18(1): 135- 42.
58. Hui DJ, Basner-Tschakarjan E, Chen Y, et al. Characterization of AAV T Cell Epitopes Presented by Splenocytes from Normal Human Donors. Mol Ther 2012; ASGCT Annual Meeting Abstracts: S557.
59. Li C, Hirsch M, Asokan A, Zeithaml B, et al. Adeno-associated virus type 2 (AAV2) capsid-specific cytotoxic T lymphocytes eliminate only vector-transduced cells coexpressing the AAV2 capsid in vivo. J Virol 2007; 81(14): 7540-7.
60. Li H, Murphy SL, Giles-Davis W, Edmonson S, et al. Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAVtransduced hepatocytes. Mol Ther 2007; 15(4): 792-800.
61. Wang L, Figueredo J, Calcedo R, et al. Cross-presentation of adeno-associated virus serotype 2 capsids activates cytotoxic T cells but does not render hepatocytes effective cytolytic targets. Hum Gene Ther 2007; 18(3): 185-94.
62. Martino AT, Basner-Tschakarjan E, Markusic DM, et al. Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 2013.
63. Wang Z, Allen JM, Riddell SR, Gregorevic P, et al. Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy. Hum Gene Ther 2007; 18(1): 18-26.
64. Mendell JR, Rodino-Klapac LR, Rosales XQ, et al. Sustained alpha-sarcoglycan gene expression after gene transfer in limbgirdle muscular dystrophy, type 2D. Ann Neurol 2010a; 68(5): 629-38.
65. Mingozzi F, Meulenberg JJ, Hui DJ, et al. AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood 2009; 114(10): 2077- 86.
66. Brantly ML, Chulay JD, Wang L, et al. Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc Natl Acad Sci U S A 2009; 106(38): 16363-8.
67. Flotte TR, Trapnell BC, Humphries M, Carey B, et al. Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing alpha1-antitrypsin: interim results. Hum Gene Ther 2011; 22(10): 1239-47.
68. Mueller C, Chulay JD, Trapnell BC, et al. Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression. J Clin Invest 2013; 123(12): 5310-8.
69. Ozeri E, Mizrahi M, Shahaf G, Lewis EC. alpha-1 antitrypsin promotes semimature, IL-10-producing and readily migrating tolerogenic dendritic cells. J immunol 2012; 189(1): 146-53.
70. Ferreira V, Petry H, Salmon F. Immune Responses to AAVVectors, the Glybera Example from Bench to Bedside. Front immunol 2014; 5S: 82.
71. Ferreira V, Twisk J, Kwikkers K, et al. Immune responses to intramuscular administration of alipogene tiparvovec (AAV1- LPL(S447X)) in a phase II clinical trial of lipoprotein lipase deficiency gene therapy. Hum Gene Ther 2014; 25(3): 180-8.
72. Velazquez VM, Bowen DG, Walker CM. Silencing of T lymphocytes by antigen-driven programmed death in recombinant adeno-associated virus vector-mediated gene therapy. Blood 2009; 113(3): 538-45.
73. Flanigan KM, Campbell K, Viollet L, et al. Anti-dystrophin T cell responses in Duchenne muscular dystrophy: prevalence and a glucocorticoid treatment effect. Hum Gene Ther 2013; 24(9): 797- 806.
74. Faust SM, Bell P, Cutler BJ, et al. CpG-depleted adeno-associated virus vectors evade immune detection. J Clin Invest 2013; 123(7): 2994-3001.
75. Finn JD, Nichols TC, Svoronos N, et al. The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy. Blood 2012; 120(23): 4521- 3.
76. Falk DJ, Mah CS, Soustek MS, et al. Intrapleural administration of AAV9 improves neural and cardiorespiratory function in Pompe disease. Mol Ther 2013; 21(9): 1661-7.
77. Manno CS, Chew AJ, Hutchison S, et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 2003; 101(8): 2963-72.
78. Stroes ES, Nierman MC, Meulenberg JJ, et al. Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients. Arterioscler Thromb Vasc Biol 2008; 28(12): 2303-4.
79. Herson S, Hentati F, Rigolet A, et al. A phase I trial of adenoassociated virus serotype 1-gamma-sarcoglycan gene therapy for limb girdle muscular dystrophy type 2C. Brain 2012; 135(Pt 2): 483-92.
80. Mendell JR, Rodino-Klapac LR, Rosales-Quintero X, et al. Limbgirdle muscular dystrophy type 2D gene therapy restores alphasarcoglycan and associated proteins. Ann Neurol 2009; 66(3): 290- 7.
81. Callejas D, Mann CJ, Ayuso E, et al. Treatment of diabetes and long-term survival after insulin and glucokinase gene therapy. Diabetes 2013; 62(5): 1718-29.
82. Brantly ML, Spencer LT, Humphries M, Conlon TJ, et al. Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adults. Hum Gene Ther 2006; 17(12): 1177-86.
83. Kornegay JN, Li J, Bogan JR, et al. Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs. Mol Ther 2010; 18(8): 1501-8.
84. Wang Z, Zhu T, Qiao C, Zhou L, et al. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat biotechno 2005; 23(3): 321-8.
85. Arnett AL, Beutler LR, Quintana A, Allen J, et al. Heparin-binding correlates with increased efficiency of AAV1- and AAV6-mediated transduction of striated muscle, but negatively impacts CNS transduction. Gene ther 2013; 20(5): 497-503.
86. Asokan A, Conway JC, Phillips JL, et al. Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle. Nat biotechno 2010; 28(1): 79-82.
87. Qiao C, Zhang W, Yuan Z, et al. Adeno-associated virus serotype 6 capsid tyrosine-to-phenylalanine mutations improve gene transfer to skeletal muscle. Hum Gene Ther 2010; 21(10): 1343-8.
88. Zhong L, Li B, Mah CS, et al. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci U S A 2008; 105(22): 7827-32.
89. Fields PA, Arruda VR, Armstrong E, et al. Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9. Mol Ther 2001; 4(3): 201-10.
90. Fisher KJ, Jooss K, Alston J, et al. Recombinant adeno-associated virus for muscle directed gene therapy. Nat Med 1997; 3(3): 306- 12.
91. Fields PA, Kowalczyk DW, Arruda VR, et al. Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX. Mol Ther 2000; 1(3): 225-35.
92. Jooss K, Yang Y, Fisher KJ, et al. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol 1998; 72(5): 4212-23.
93. Lin SW, Hensley SE, Tatsis N, et al. Recombinant adenoassociated virus vectors induce functionally impaired transgene product-specific CD8+ T cells in mice. J Clin Invest 2007; 117(12): 3958-70.
94. Sarukhan A, Camugli S, Gjata B, von Boehmer H, Danos O, Jooss K. Successful interference with cellular immune responses to immunogenic proteins encoded by recombinant viral vectors. J Virol 2001; 75(1): 269-77.
95. Xu D, Walker CM. Continuous CD8(+) T-cell priming by dendritic cell cross-presentation of persistent antigen following adenoassociated virus-mediated gene delivery. J Virol 2011; 85(22): 12083-6.
96. Veron P, Allo V, Riviere C, et al. Major subsets of human dendritic cells are efficiently transduced by self-complementary adenoassociated virus vectors 1 and 2. J Virol 2007; 81(10): 5385-94.
97. Ohshima S, Shin JH, Yuasa K, et al. Transduction efficiency and immune response associated with the administration of AAV8 vector into dog skeletal muscle. Mol Ther 2009; 17(1): 73-80.
98. Gernoux G, Guilbaud M, Dubreil L, et al. Early interaction of adeno-associated virus serotype 8 vector with the host immune system following intramuscular delivery results in weak but detectable lymphocyte and dendritic cell transduction. Hum Gene Ther 2015; 26(1): 1-13.
99. Brown BD, Venneri MA, Zingale A, et al. Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer. Nat Med 2006; 12(5): 585-91.
100. Boisgerault F, Gross DA, Ferrand M, et al. Prolonged gene expression in muscle is achieved without active immune tolerance using microRNA 142.3p-regulated rAAV gene transfer. Hum Gene Ther 2013.
101. Carpentier M, Lorain S, Chappert P, et al. Intrinsic transgene immunogenicity gears CD8 T-cell priming after rAAV-mediated muscle gene transfer. Mol Ther 2014.
102. Majowicz A, Maczuga P, Kwikkers KL, et al. Mir-142-3p target sequences reduce transgene-directed immunogenicity following intramuscular adeno-associated virus 1 vector-mediated gene delivery. j gene med 2013; 15(6-7): 219-32.
103. Ferrand M, Galy A, Boisgerault F. A dystrophic muscle broadens the contribution and activation of immune cells reacting to rAAV gene transfer. Gene ther 2014; 21(9): 828-39.
104. Mays LE, Wang L, Lin J, et al. AAV8 induces tolerance in murine muscle as a result of poor APC transduction, T cell exhaustion, and minimal MHCI upregulation on target cells. Mol Ther 2014; 22(1): 28-41.
105. Mendell JR, Campbell K, Rodino-Klapac L, et al. Dystrophin immunity in Duchenne's muscular dystrophy. New Eng j med 2010b; 363(15): 1429-37.
106. Mingozzi F, Liu YL, Dobrzynski E, Kaufhold A, et al. Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J Clin Invest 2003; 111(9): 1347-56.
107. Cao O, Hoffman BE, Moghimi B, et al. Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B. Mol Ther 2009; 17(10): 1733-42.
108. Rogers GL, Martino AT, Zolotukhin I, et al. Role of the vector genome and underlying factor IX mutation in immune responses to AAV gene therapy for hemophilia B. J translational med 2014; 12: 25.
109. Herzog RW, Mount JD, Arruda VR, et al. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation. Mol Ther 2001; 4(3): 192-200.
110. Herzog RW, Yang EY, Couto LB, et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med 1999; 5(1): 56-63.
111. Herzog RW, Fields PA, Arruda VR, et al. Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy. Hum Gene Ther 2002; 13(11): 1281-91.
112. Martino AT, Suzuki M, Markusic DM, et al. The genome of selfcomplementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver. Blood 2011; 117(24): 6459-68.
113. Kishnani PS, Goldenberg PC, DeArmey SL,et al. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol genetics metab 2010; 99(1): 26-33.
114. Markusic DM, Hoffman BE, Perrin GQ, et al. Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies. EMBO mol med 2013; 5(11): 1698-709.
115. Finn JD, Ozelo MC, Sabatino DE, et al. Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy. Blood 2010; 116(26): 5842-8.
116. Arruda VR, Schuettrumpf J, Herzog RW, et al. Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1. Blood 2004; 103(1): 85-92.
117. Margaritis P, Roy E, Aljamali MN, et al. Successful treatment of canine hemophilia by continuous expression of canine FVIIa. Blood 2009; 113(16): 3682-9.
118. Gao G, Lebherz C, Weiner DJ, Grant R, et al. Erythropoietin gene therapy leads to autoimmune anemia in macaques. Blood 2004; 103(9): 3300-2.
119. Turk R, Sterrenburg E, van der Wees CG, et al. Common pathological mechanisms in mouse models for muscular dystrophies. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2006; 20(1): 127- 9.
120. Porter JD, Guo W, Merriam AP, Khanna S, et al. Persistent overexpression of specific CC class chemokines correlates with macrophage and T-cell recruitment in mdx skeletal muscle. Neuromuscular disorders : NMD 2003; 13(3): 223-35.
121. Connolly AM, Pestronk A, Mehta S, et al. Primary alphasarcoglycan deficiency responsive to immunosuppression over three years. Muscle & nerve 1998; 21(11): 1549-53.
122. Eghtesad S, Jhunjhunwala S, Little SR, Clemens PR. Rapamycin ameliorates dystrophic phenotype in mdx mouse skeletal muscle. Mol med 2011; 17(9-10): 917-24.
123. Sciorati C, Buono R, Azzoni E, Casati S, et al. Co-administration of ibuprofen and nitric oxide is an effective experimental therapy for muscular dystrophy, with immediate applicability to humans. British j pharmaco 2010; 160(6): 1550-60.
124. Farini A, Meregalli M, Belicchi M, et al. T and B lymphocyte depletion has a marked effect on the fibrosis of dystrophic skeletal muscles in the scid/mdx mouse. J pathol 2007; 213(2): 229-38.
125. Farini A, Sitzia C, Navarro C, D'Antona G, et al. Absence of T and B lymphocytes modulates dystrophic features in dysferlin deficient animal model. Exper cell res 2012; 318(10): 1160-74.
126. Spencer MJ, Montecino-Rodriguez E, et al. Helper (CD4(+)) and cytotoxic (CD8(+)) T cells promote the pathology of dystrophindeficient muscle. Clinic immunol 2001; 98(2): 235-43.
127. Gussoni E, Pavlath GK, Miller RG, et al. Specific T cell receptor gene rearrangements at the site of muscle degeneration in Duchenne muscular dystrophy. J immunol 1994; 153(10): 4798- 805.
128. Yue Y, Ghosh A, Long C, et al. A single intravenous injection of adeno-associated virus serotype-9 leads to whole body skeletal muscle transduction in dogs. Mol Ther 2008; 16(12): 1944-52.
129. Shin JH, Yue Y, Srivastava A, et al. A simplified immune suppression scheme leads to persistent micro-dystrophin expression in Duchenne muscular dystrophy dogs. Hum Gene Ther 2012; 23(2): 202-9.
130. Wang Z, Kuhr CS, Allen JM, et al. Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. Mol Ther 2007; 15(6): 1160-6.
131. Wang Z, Tapscott SJ, Chamberlain JS, Storb R. Immunity and AAV-Mediated Gene Therapy for Muscular Dystrophies in Large Animal Models and Human Trials. Front Microbiol 2011; 2: 201.
132. Koo T, Okada T, Athanasopoulos T, et al. Long-term functional adeno-associated virus-microdystrophin expression in the dystrophic CXMDj dog. j gene med 2011; 13(9): 497-506.
133. Thanh LT, Nguyen TM, Helliwell TR, Morris GE. Characterization of revertant muscle fibers in Duchenne muscular dystrophy, using exon-specific monoclonal antibodies against dystrophin. Am J Hum Genet 1995; 56(3): 725-31.
134. Pigozzo SR, Da Re L, Romualdi C, et al. Revertant fibers in the mdx murine model of Duchenne muscular dystrophy: an age- and muscle-related reappraisal. PloS one 2013; 8(8): e72147.
135. Arechavala-Gomeza V, Kinali M, Feng L, et al. Revertant fibres and dystrophin traces in Duchenne muscular dystrophy: implication for clinical trials. Neuromuscular disorders : NMD 2010; 20(5): 295-301.
136. Mendell JR, Sahenk Z, Malik V, et al. A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy. Mol Ther 2015; 23(1): 192-201.
137. Fairclough RJ, Wood MJ, Davies KE. Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches. Nat rev Genetics 2013; 14(6): 373-8.
138. Tinsley J, Deconinck N, Fisher R, et al. Expression of full-length utrophin prevents muscular dystrophy in mdx mice. Nat Med 1998; 4(12): 1441-4.
139. Odom GL, Gregorevic P, Allen JM, Finn E, Chamberlain JS. Microutrophin delivery through rAAV6 increases lifespan and improves muscle function in dystrophic dystrophin/utrophindeficient mice. Mol Ther 2008; 16(9): 1539-45.
140. Selsby JT, Morine KJ, Pendrak K, et al. Rescue of dystrophic skeletal muscle by PGC-1alpha involves a fast to slow fiber type shift in the mdx mouse. PloS one 2012; 7(1): e30063.
141. Strimpakos G, Corbi N, Pisani C, et al. Novel adeno-associated viral vector delivering the utrophin gene regulator jazz counteracts dystrophic pathology in mdx mice. J Cell Physiol 2014; 229(9): 1283-91.
142. Ebihara S, Guibinga GH, Gilbert R, et al. Differential effects of dystrophin and utrophin gene transfer in immunocompetent muscular dystrophy (mdx) mice. Physiol Genomics 2000; 3(3): 133-44.
143. Belanto JJ, Mader TL, Eckhoff MD, et al. Microtubule binding distinguishes dystrophin from utrophin. Proc Natl Acad Sci U S A 2014; 111(15): 5723-8.
144. Tidball JG, Villalta SA. Regulatory interactions between muscle and the immune system during muscle regeneration. American journal of physiology Regulatory, integrative and comparative physiology 2010; 298(5): R1173-87.
145. Villalta SA, Nguyen HX, Deng B, et al. Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy. Human molecular genetics 2009; 18(3): 482-96.
146. Wehling M, Spencer MJ, Tidball JG. A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice. J cell biol 2001; 155(1): 123-31.
147. Mantovani A, Sica A, Sozzani S, et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends in immunol 2004; 25(12): 677-86.
148. Yuasa K, Sakamoto M, Miyagoe-Suzuki Y, et al. Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product. Gene ther 2002; 9(23): 1576-88.
149. Villalta SA, Rinaldi C, Deng B, et al. Interleukin-10 reduces the pathology of mdx muscular dystrophy by deactivating M1 macrophages and modulating macrophage phenotype. Human mol genetics 2011; 20(4): 790-805.
150. Burzyn D, Kuswanto W, Kolodin D, et al. A special population of regulatory T cells potentiates muscle repair. Cell 2013; 155(6): 1282-95.
151. Villalta SA, Rosenthal W, Martinez L, et al. Regulatory T cells suppress muscle inflammation and injury in muscular dystrophy. Sci Transl Med 2014; 6(258): 258ra142.
152. Gross DA, Leboeuf M, Gjata B, et al. CD4+CD25+ regulatory T cells inhibit immune-mediated transgene rejection. Blood 2003; 102(13): 4326-8.
153. Korn T, Anderson AC, Bettelli E, et al. The dynamics of effector T cells and Foxp3+ regulatory T cells in the promotion and regulation of autoimmune encephalomyelitis. J neuroimmunology 2007; 191(1-2): 51-60.
154. Bailey-Bucktrout SL, Martinez-Llordella M, Zhou X, et al. Selfantigen- driven activation induces instability of regulatory T cells during an inflammatory autoimmune response. Immunity 2013; 39(5): 949-62.
155. Saadoun D, Rosenzwajg M, Joly F, Six A, et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. New Eng j med 2011; 365(22): 2067-77.
156. Dressman D, Araishi K, Imamura M, et al. Delivery of alpha- and beta-sarcoglycan by recombinant adeno-associated virus: efficient rescue of muscle, but differential toxicity. Hum Gene Ther 2002; 13(13): 1631-46.
157. Fougerousse F, Bartoli M, Poupiot J, et al. Phenotypic correction of alpha-sarcoglycan deficiency by intra-arterial injection of a musclespecific serotype 1 rAAV vector. Mol Ther 2007; 15(1): 53-61.
158. Cordier L, Gao GP, Hack AA, et al. Muscle-specific promoters may be necessary for adeno-associated virus-mediated gene transfer in the treatment of muscular dystrophies. Hum Gene Ther 2001; 12(2): 205-15.
159. Su LT, Gopal K, Wang Z, et al. Uniform scale-independent gene transfer to striated muscle after transvenular extravasation of vector. Circulation 2005; 112(12): 1780-8.
160. Toromanoff A, Cherel Y, Guilbaud M, et al. Safety and efficacy of regional intravenous (r.i.) versus intramuscular (i.m.) delivery of rAAV1 and rAAV8 to nonhuman primate skeletal muscle. Mol Ther 2008; 16(7): 1291-9.
161. Toromanoff A, Adjali O, Larcher T, et al. Lack of immunotoxicity after regional intravenous (RI) delivery of rAAV to nonhuman primate skeletal muscle. Mol Ther 2010; 18(1): 151-60.
162. Rodino-Klapac LR, Montgomery CL, Bremer WG, et al. Persistent expression of FLAG-tagged micro dystrophin in nonhuman primates following intramuscular and vascular delivery. Mol Ther 2010; 18(1): 109-17.
163. Fan Z, Kocis K, Valley R, Howard JF, et al. Safety and feasibility of high-pressure transvenous limb perfusion with 0.9% saline in human muscular dystrophy. Mol Ther 2012; 20(2): 456-61.
164. Haurigot V, Mingozzi F, Buchlis G, Hui D, et al. Safety of AAV factor IX peripheral transvenular gene delivery to muscle in hemophilia B dogs. Mol Ther 2010.
165. Bartel M, Schaffer D, Buning H. Enhancing the Clinical Potential of AAV Vectors by Capsid Engineering to Evade Pre-Existing Immunity. Front Microbiol 2011; 2: 204.
166. Buchlis G, Podsakoff GM, Radu A, et al. Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer. Blood 2012; 119(13): 3038-41.
167. McMillan HJ, Gregas M, Darras BT, Kang PB. Serum transaminase levels in boys with Duchenne and Becker muscular dystrophy. Pediatrics 2011; 127(1): e132-6.